Sapablursen in Beta-Thalassemia: NCT04059406 Clinical Landscape Report 2026
Explore the PatSnap Life Sciences MCP marketplace
This Clinical Landscape Report was built with PatSnap Life Sciences MCP workflows. Clinical Trials MCP supplies protocol and result records, Drug & Asset MCP adds asset context, and Company & Deal Intelligence MCP resolves sponsor background. Use the same structured MCP building blocks in your research workflow.
Data snapshot: 28 September 2026. This strategic research report is not medical, regulatory or investment advice. Trial status and dates can change.
Phase 2
Clinical phase
Terminated
Recruitment status
29
Planned enrollment
2023-03-28
Primary-completion proxy
Executive view
NCT04059406 evaluates Sapablursen in Beta-Thalassemia. The disclosed sponsor is Ionis Pharmaceuticals, Inc., the design is Interventional, and the geographic footprint is Lebanon, Greece, Turkey, Thailand, Australia. The first listed primary endpoint is Percentage of Participants With a ≥1.0 Grams Per Deciliter (g/dL) Increase From Baseline in Hemoglobin (Hb) at Week 27, assessed over Baseline and Week 27.
The key landscape question is whether this protocol can generate a clinically interpretable signal relative to nearby programs. Phase alone is not a measure of evidence quality. Endpoint relevance, comparator choice, masking, enrollment feasibility, patient selection, country coverage and follow-up must be considered together.
PatSnap MCP Servers make this assessment reproducible by keeping protocol facts, result evidence, asset attributes and sponsor identity in separate structured calls.
How the MCP evidence stack was assembled
Clinical Trials MCP clinical_trial_fetch retrieved the design, outcomes, phase, status, enrollment, sponsor, countries and timing for NCT04059406 and selected peers. clinical_trial_result_fetch supplied detailed result records from the wider Beta-Thalassemia landscape. Drug & Asset MCP drug_fetch was queried for Sapablursen, while Company & Deal Intelligence MCP organization_fetch was queried for Ionis Pharmaceuticals, Inc..
This separation reduces a common diligence error: treating a registry label, a company description or a result excerpt as if each represented the complete evidence package. Explore the source workflow at the PatSnap MCP marketplace.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Readout proxy |
|---|---|---|---|---|---|---|
| NCT04059406 | Sapablursen | Phase 2 / Terminated | Ionis Pharmaceuticals, Inc. | Lebanon, Greece, Turkey, Thailand, Australia | Percentage of Participants With a ≥1.0 Grams Per Deciliter (g/dL) Increase From Baseline in Hemoglobin (Hb) at Week 27 Baseline and Week 27 | 2023-03-28 |
| NCT04474626 | Isoquercetin | Phase 2 / Withdrawn | Beth Israel Deaconess Medical Center, Inc. | Geography not reported | Change in sP Selectin levels with isoquercetin baseline to 28 Days | 2022-12-31 |
| NCT04432623 | Benserazide | Phase 1/2 / Enrolling by invitation | PHOENICIA BIOSCIENCES, INC. | Canada, United States | Safety and Tolerability 12 to 24 weeks | 2026-02-28 |
| NCT04411082 | Tovinontrine | Phase 2 / Terminated | Cardurion Pharmaceuticals, Inc. | Lebanon, Greece, Netherlands, Turkey, Morocco, Denmark, United Kingdom, Italy, Malaysia, Israel, United States, France, Tunisia | IMR-687 Safety and Tolerability Baseline to Week 40 | 2022-03-11 |
| NCT04364269 | Vamifeport hydrochloride | Phase 2 / Completed | Vifor (International) AG | Lebanon, Greece, Italy, Israel, Thailand | Number of Participants With Treatment-Emergent Adverse Events (TEAEs) From baseline to Week 16 | 2021-10-11 |
The table aligns endpoints, sponsors, phases, geographies and readout proxies. It is descriptive, not a head-to-head efficacy comparison. Differences in population, baseline risk, intervention schedule and follow-up can dominate apparent cross-trial differences.
Reproduce the trial-to-asset workflow with PatSnap MCP
Protocol design and endpoint interpretation
NCT04059406 is a Phase 2, terminated study with 29 planned participants. Allocation is Randomized, masking is None (Open Label), and the intervention model is Single Group Assignment.
The primary endpoint is “Percentage of Participants With a ≥1.0 Grams Per Deciliter (g/dL) Increase From Baseline in Hemoglobin (Hb) at Week 27” over “Baseline and Week 27.” The retrieved endpoint description is: Blood hemoglobin.
Interpretation should test whether the endpoint captures a clinically meaningful change, whether its time horizon matches the proposed biology, and whether treatment discontinuation or missing data can bias the estimate. The planned enrollment of 29 should be assessed against expected effect size, event frequency, multiplicity, subgroup plans and attrition.
No named control drug was returned in the protocol field set. A placebo comparator can strengthen internal efficacy assessment, while an active comparator may better test clinical differentiation. Single-arm and open-label programs require greater weight on objective outcomes, independent assessment and external benchmarks.
Indexed readouts in the surrounding landscape
5 recent result records were selected as contextual evidence for Beta-Thalassemia. These records do not establish direct evidence for NCT04059406 unless the registration number matches.
Reduced Intensity Conditioning (RIC) Regimen for Patients With Non-malignant Disorders
Phase 2; n=56; Number of Participants With Engraftment = 53 Participants Source: https://clinicaltrials.gov/ct2/show/results/NCT01050855
CRISPR-Cas12a Gene Editing of HBG1 and HBG2 Promoters to Treat β-Thalassemia
Phase 1/2; n=9; Adverse Event: decreased lymphocyte counts = One patient had decreased lymphocyte counts attributed to reni-cel Source: https://pubmed-ncbi-nlm-nih-gov.libproxy1.nus.edu.sg/41931048/
REDEFINING CURATIVE HORIZONS IN THALASSEMIA MAJOR: 100% SURVIVAL FOLLOWING ALTERNATIVE DONOR HSCT IN A RESOURCE- LIMITED SETTING
Not Applicable; n=33; EFS = 50.0 % ; EFS = 100.0 % Source: https://www.ebmt.org/sites/default/files/2026-03/AM26_Abstracts%20Book_final_v.pdf
Result fields should be reconciled with the source record before quantitative comparison. Population definitions, analysis sets, dose cohorts, estimands, confidence intervals, rescue therapy and follow-up can materially change the meaning of a numerical endpoint. Clinical Trials MCP supports repeatable refreshes as result records change.
Asset and sponsor context
Sapablursen is indexed as ASO with TMPRSS6 biology and a global stage of Phase 3. The asset profile lists Ionis Pharmaceuticals, Inc. as an originator or developer.
Ionis Pharmaceuticals, Inc. is indexed in United States with the website http://www.ionispharma.com. Ionis Pharmaceuticals specializes in the discovery and development of RNA-targeted drugs. The record lists 75 development-stage drug assets.
For execution diligence, monitor sponsor ownership, collaborator additions, site expansion, protocol amendments and enrollment revisions. A change in ownership or geography can alter operational confidence as well as the commercial meaning of a future readout.
Development white space
- Endpoint white space. Determine whether a more patient-relevant outcome, longer durability window or blinded central assessment would resolve uncertainty left by the current endpoint.
- Population white space. Test biomarker-defined, treatment-line or risk-stratified subgroups where effect size and unmet need could be clearer.
- Comparator white space. Identify whether the study can support differentiation against the current standard of care rather than only activity against baseline or placebo.
- Geographic white space. Assess whether the disclosed footprint supports recruitment, regulatory transferability and commercial generalizability.
- Sequencing white space. Clarify whether Sapablursen is intended for monotherapy, combination, maintenance, rescue or an earlier treatment line.
White space should be framed as an unanswered development question, not merely an unoccupied mechanism label. A credible program closes a measurable clinical uncertainty with a design that can be executed and interpreted.
Strategic implications and next readouts
For sponsors, the endpoint hierarchy, safety window, enrollment pace and protocol amendment history should all support the same target product profile. Advancement criteria should be set before the readout and tied to clinical effect, uncertainty, tolerability and operational feasibility.
For business-development teams, differentiation may come from a sharper population, stronger comparator, more durable benefit, simpler delivery or clearer sequencing role. For investors, the central risk is evidence quality relative to time and capital, not the phase label in isolation.
Track recruitment status, enrollment changes, primary-completion timing, endpoint revisions, new result records, sponsor ownership and collaborator changes. Re-run the PatSnap MCP workflow when a surrogate becomes a clinical outcome, a single-country study expands, the comparator changes or a new result materially shifts the competitive benchmark.
Source trail and bottom line
Anchor trial: NCT04059406
Protocol source: https://clinicaltrials.gov/study/NCT04059406
MCP sources: Clinical Trials MCP (clinical_trial_fetch and clinical_trial_result_fetch); Drug & Asset MCP (drug_fetch); Company & Deal Intelligence MCP (organization_fetch).
Data snapshot: 28 September 2026.
Sapablursen in Beta-Thalassemia is best understood through the interaction of protocol design, surrounding readouts, asset context and sponsor execution. The current record makes Percentage of Participants With a ≥1.0 Grams Per Deciliter (g/dL) Increase From Baseline in Hemoglobin (Hb) at Week 27 and 2023-03-28 the leading decision points.
Build and refresh clinical landscape reports with PatSnap MCP
